Petros Pharmaceuticals enters research agreement with Mass General for oxygenation sensor in erectile therapy

Petros Pharmaceuticals, Inc.

Signed Sponsored Research Agreement and Option Agreement with Wellman Center of Massachusetts General Hospital.
Goal is to evaluate tissue-specific oxygenation sensor to monitor success of Erectile Device Therapy.
Option agreement allows Petros to negotiate an exclusive license of the sensor technology for specific human tissues.
Sensor intended to provide bio-sensor feedback for at-home penile therapy, enhancing existing erectile device therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.